Konstantia Angelidou1, Peter W Hunt2, Alan L Landay3, Cara C Wilson4, Benigno Rodriguez5, Steven G Deeks2, Ronald J Bosch1, Michael M Lederman5. 1. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 2. San Francisco General Hospital, University of California. 3. Rush University Medical Center, Chicago, Illinois. 4. University of Colorado Hospital, Aurora. 5. Case Western Reserve University School of Medicine, Cleveland, Ohio.
Abstract
Background: We examined changes in soluble inflammatory cytokines and T-cell activation after antiretroviral therapy (ART) initiation in an AIDS Clinical Trials Group (ACTG) nested case-control study. Methods: Cases were 143 human immunodeficiency virus (HIV)-infected adults who developed a non-AIDS event; 315 controls remained event-free. Specimens were tested pre-ART, year 1 post-ART, and at the visit preceding the event. Conditional logistic regression evaluated the associations of biomarker changes with non-AIDS events. Results: Inflammatory and most activation biomarkers declined from pre-ART to year 1 for cases and controls. Subsequently, inflammatory biomarkers remained mostly stable in controls but not cases. Cellular activation markers generally declined for both cases and controls between year 1 and the pre-event sampling. Controls with greater pre-ART RNA levels or lower CD4+ levels had higher biomarker levels while also experiencing greater biomarker declines in the first year of ART. Changes in biomarkers to year 1 showed no significant associations with non-AIDS events. Cases, however, had significantly greater increases in all plasma biomarkers (but not cellular activation) from year 1 to the visit preceding the event. Conclusions: Inflammation increases prior to non-AIDS events in treated HIV-infected adults. These biomarker changes may reflect subclinical disease processes or other alterations in the inflammatory environment that causally contribute to disease. Clinical Trials Registration: NCT00001137.
Background: We examined changes in soluble inflammatory cytokines and T-cell activation after antiretroviral therapy (ART) initiation in an AIDS Clinical Trials Group (ACTG) nested case-control study. Methods: Cases were 143 human immunodeficiency virus (HIV)-infected adults who developed a non-AIDS event; 315 controls remained event-free. Specimens were tested pre-ART, year 1 post-ART, and at the visit preceding the event. Conditional logistic regression evaluated the associations of biomarker changes with non-AIDS events. Results: Inflammatory and most activation biomarkers declined from pre-ART to year 1 for cases and controls. Subsequently, inflammatory biomarkers remained mostly stable in controls but not cases. Cellular activation markers generally declined for both cases and controls between year 1 and the pre-event sampling. Controls with greater pre-ART RNA levels or lower CD4+ levels had higher biomarker levels while also experiencing greater biomarker declines in the first year of ART. Changes in biomarkers to year 1 showed no significant associations with non-AIDS events. Cases, however, had significantly greater increases in all plasma biomarkers (but not cellular activation) from year 1 to the visit preceding the event. Conclusions: Inflammation increases prior to non-AIDS events in treated HIV-infected adults. These biomarker changes may reflect subclinical disease processes or other alterations in the inflammatory environment that causally contribute to disease. Clinical Trials Registration: NCT00001137.
Authors: Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin Journal: AIDS Date: 2011-11-13 Impact factor: 4.177
Authors: Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: Ashwin Balagopal; David M Asmuth; Wei-Teng Yang; Thomas B Campbell; Nikhil Gupte; Laura Smeaton; Cecilia Kanyama; Beatriz Grinsztejn; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh G Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Xiao-Dong Li; Richard B Pollard; Richard D Semba; David L Thomas; Robert C Bollinger; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.731
Authors: Nikolas I Wada; Jay H Bream; Otoniel Martínez-Maza; Bernard Macatangay; Shannon R Galvin; Joseph B Margolick; Lisa P Jacobson Journal: Clin Infect Dis Date: 2016-06-25 Impact factor: 9.079
Authors: Babafemi Taiwo; Roy M Matining; Lu Zheng; Michael M Lederman; Charles R Rinaldo; Peter S Kim; Baiba I Berzins; Daniel R Kuritzkes; Amy Jennings; Joseph J Eron; Cara C Wilson Journal: J Antimicrob Chemother Date: 2013-04-18 Impact factor: 5.790
Authors: Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-11-12 Impact factor: 4.254
Authors: Joshua J Anzinger; Tiffany R Butterfield; Thomas A Angelovich; Suzanne M Crowe; Clovis S Palmer Journal: J Immunol Res Date: 2014-06-12 Impact factor: 4.818
Authors: Martin Hoenigl; Carlee B Moser; Nicholas Funderburg; Ronald Bosch; Amy Kantor; Yonglong Zhang; Jesper Eugen-Olsen; Malcolm Finkelman; Jochen Reiser; Alan Landay; Daniela Moisi; Michael M Lederman; Sara Gianella Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Rebeca S De Pablo-Bernal; M Reyes Jimenez-Leon; Laura Tarancon-Diez; Alicia Gutierrez-Valencia; Ana Serna-Gallego; Maria Trujillo-Rodriguez; Ana I Alvarez-Rios; Yusnelkis Milanes-Guisado; Nuria Espinosa; Cristina Roca-Oporto; Pompeyo Viciana; Luis F Lopez-Cortes; Ezequiel Ruiz-Mateos Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Brandilyn A Peters; Jee-Young Moon; David B Hanna; Olaf Kutsch; Margaret Fischl; Caitlin A Moran; Adaora A Adimora; Stephen Gange; Nadia R Roan; Katherine G Michel; Michael Augenbraun; Anjali Sharma; Alan Landay; Seema Desai; Robert C Kaplan Journal: J Infect Dis Date: 2022-02-15 Impact factor: 7.759
Authors: Jehad Alzahrani; Tabinda Hussain; David Simar; Riya Palchaudhuri; Mohamed Abdel-Mohsen; Suzanne M Crowe; George W Mbogo; Clovis S Palmer Journal: EBioMedicine Date: 2019-07-18 Impact factor: 8.143
Authors: Mark J Siedner; Mwebesa Bosco Bwana; Stephen Asiimwe; Gideon Amanyire; Nicholas Musinguzi; Jose Castillo-Mancilla; Russell P Tracy; Ingrid T Katz; David R Bangsberg; Peter W Hunt; Catherine Orrell; Jessica E Haberer Journal: J Infect Dis Date: 2019-08-30 Impact factor: 5.226
Authors: Lauren F Collins; Anandi N Sheth; C Christina Mehta; Susanna Naggie; Elizabeth T Golub; Kathryn Anastos; Audrey L French; Seble Kassaye; Tonya N Taylor; Margaret A Fischl; Adaora A Adimora; Mirjam-Colette Kempf; Frank J Palella; Phyllis C Tien; Ighovwerha Ofotokun Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Samuel R Schnittman; Helen Byakwaga; Yap Boum; Jerome Kabakyenga; Lynn T Matthews; Tricia H Burdo; Yong Huang; Russell P Tracy; Jessica E Haberer; Annet Kembabazi; Angela Kaida; Daniela Moisi; Michael M Lederman; David R Bangsberg; Jeffrey N Martin; Peter W Hunt Journal: Open Forum Infect Dis Date: 2021-05-17 Impact factor: 3.835